<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534610</url>
  </required_header>
  <id_info>
    <org_study_id>AN010-13</org_study_id>
    <nct_id>NCT02534610</nct_id>
  </id_info>
  <brief_title>Analgesic Benefit of Preoperative vs. Postoperative Etoricoxib in Total Knee Arthroplasty</brief_title>
  <official_title>Is There Any Analgesic Benefit From Preoperative vs. Postoperative Etoricoxib Administration in Total Knee Arthroplasty?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foisor Orthopedics Clinical Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foisor Orthopedics Clinical Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy of preemptive versus postoperative administration of etoricoxib in
      total knee arthroplasty (TKA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators conducted a prospective randomized controlled study in 165 patients
      American Society of Anesthesiologists (ASA) score I-III scheduled for primary TKA, divided in
      3 groups: group A (Etoricoxib 120 mg orally one hour before surgery), group B (Etoricoxib 120
      mg orally at the end of surgery) and group C placebo. Surgery has been performed under spinal
      anesthesia.

      All groups received postoperative analgesia when Numeric Rating Scale (NRS) over 3 with
      intravenous (IV) Perfalgan and morphine on demand for the following 48 h.

      The effectiveness was evaluated by the time from the initiation of spinal anesthesia until
      the first analgesic dose at NRS &gt; 3, the total amount of morphine in the first 24 and 48
      hours postoperative, the side effects and necessary amount of adjuvant medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine consumption</measure>
    <time_frame>At 48 hour postoperative</time_frame>
    <description>Amount of IV and subcutaneous (SC) morphine (mg) required to reach NRS under 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with side effects of drugs used</measure>
    <time_frame>48 hour postoperative</time_frame>
    <description>number of patients with postoperative nausea and vomiting (PONV) or respiratory depression or gastric complaint or allergic reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>At 48 hours postoperative</time_frame>
    <description>Time from spinal anesthesia until the first rescue morphine analgesia</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group ETORICOXIB PREOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative (1 h) per os (PO) 120 mg Etoricoxib (Arcoxia) and 1 placebo pill PO at the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group ETORICOXIB POSTOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative (1 h) 1 placebo pill PO and 120 mg Etoricoxib PO at the end of surgery (Arcoxia).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo pill PO 1 h preoperative and 1 placebo pill PO postoperative at the end of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib</intervention_name>
    <description>120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.</description>
    <arm_group_label>Group ETORICOXIB PREOP</arm_group_label>
    <arm_group_label>Group ETORICOXIB POSTOP</arm_group_label>
    <other_name>Arcoxia</other_name>
    <other_name>Tauxib</other_name>
    <other_name>Algix</other_name>
    <other_name>Exxiv</other_name>
    <other_name>Etozox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.</description>
    <arm_group_label>Group ETORICOXIB PREOP</arm_group_label>
    <arm_group_label>Group ETORICOXIB POSTOP</arm_group_label>
    <arm_group_label>Group PLACEBO</arm_group_label>
    <other_name>Sham pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-III

          -  weight (kilos) over 40 kg

          -  height (centimeters) over 155 cm

          -  non-anemic

          -  indication for primary TKA (total knee arthroplasty)

        Exclusion Criteria:

          -  history of asthma

          -  peptic ulcer

          -  severe hepatic or renal dysfunction

          -  neuropathies

          -  bleeding disorders

          -  uncooperative

          -  drug abuse

          -  sensibility to etoricoxib

          -  paracetamol or morphine

          -  long acting nonsteroidal antiinflammatory drugs (NSAID) in the last 4 days
             preoperative

          -  cerebrovascular and peripheric vascular disease

          -  arterial hypertension (HTA) not adequately controlled

          -  congestive heart failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Munteanu Ana-Maria, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foisor Orthopedics Clinical Hospital Bucharest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stoica I Cristian, MD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Foisor Orthopedics Clinical Hospital Bucharest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foisor Orthopedics Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>021382</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <results_reference>
    <citation>Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Curr Opin Anaesthesiol. 2009 Oct;22(5):588-93. doi: 10.1097/ACO.0b013e328330373a. Review.</citation>
    <PMID>19606021</PMID>
  </results_reference>
  <results_reference>
    <citation>Sinatra R. Role of COX-2 inhibitors in the evolution of acute pain management. J Pain Symptom Manage. 2002 Jul;24(1 Suppl):S18-27. Review.</citation>
    <PMID>12204484</PMID>
  </results_reference>
  <results_reference>
    <citation>Singer MA. Interaction of dibucaine and propranolol with phospholipid bilayer membranes-effect of alterations in fatty acyl composition. Biochem Pharmacol. 1977 Jan 1;26(1):51-7.</citation>
    <PMID>188426</PMID>
  </results_reference>
  <results_reference>
    <citation>Dahl JB, Møiniche S. Pre-emptive analgesia. Br Med Bull. 2004 Dec 13;71:13-27. Print 2004. Review.</citation>
    <PMID>15596866</PMID>
  </results_reference>
  <results_reference>
    <citation>Møiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology. 2002 Mar;96(3):725-41. Review.</citation>
    <PMID>11873051</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee BH, Park JO, Suk KS, Kim TH, Lee HM, Park MS, Lee SH, Park S, Lee JY, Ko SK, Moon SH. Pre-emptive and multi-modal perioperative pain management may improve quality of life in patients undergoing spinal surgery. Pain Physician. 2013 May-Jun;16(3):E217-26.</citation>
    <PMID>23703420</PMID>
  </results_reference>
  <results_reference>
    <citation>Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013 Oct 22;(10):CD004233. doi: 10.1002/14651858.CD004233.pub4. Review.</citation>
    <PMID>24150982</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Foisor Orthopedics Clinical Hospital</investigator_affiliation>
    <investigator_full_name>Munteanu Ana Maria, MD, PhD</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>preemptive</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>etoricoxib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

